FEIBA® [anti-inhibitor coagulant complex]

For more than 40 years, FEIBA has helped treat patients
with hemophilia A and B who have inhibitors.1,2

FEIBA reached distribution of more than 7 billion units (1975–2016) and ~2 million patient treatments.3 It was first licensed in the United States as FEIBA VH and is now available as FEIBA NF.4,5

For information about FEIBA, please select your status below.

for healthcare
professionals

I am a healthcare
professional in the U.S.

for patients
and caregivers

I am a patient or
caregiver in the U.S.

Cookie Use Notification

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies
as set out in our cookie notice. Please read our cookie notice for more information on the cookies we use and how to delete or block the use of cookies.

      Find out more

See LessMore

What is FEIBA?

FEIBA is an Anti-Inhibitor Coagulant Complex approved for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes...

Detailed Important Risk Information

What is FEIBA?

FEIBA is an Anti-Inhibitor Coagulant Complex approved for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes
  • Use around the time of surgery
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Detailed Important Risk Information

  • Blood clots that block blood vessels and their effects have been reported during post-marketing surveillance following infusion of FEIBA, particularly following administration of high doses (above 200 units per kg per day) and/or in patients at risk for forming blood clots.
  • If you experience any of these side effects, call your doctor right away.
References: 1. FEIBA [Prescribing Information]. Lexington, MA: Baxalta US Inc.; 2019.
2. Rota M, Cortesi PA, Crea R, et al. Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. Blood Adv. 2017;1(26):2637-2642. 3. Crea R, Novack A, Reininger AJ, et al. Four decade cumulative review of thrombo-embolic events reported with the use of activated prothrombin complex concentrate in congenital haemophilia. Blood. 2016;128:5031. 4. FEIBA US Prescribing Information. Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia. 2006;12(suppl 6):54-61. 5. Turecek PL, Schwarz HP. Factor eight inhibitor bypassing activity. In: Bertolini J, Goss N, Curling J, eds. Production of Plasma Proteins for Therapeutic Use. 1st ed. Hoboken, NJ: John Wiley & Sons; 2013:29-63.